Michael Wiese

4.4k total citations
108 papers, 3.8k citations indexed

About

Michael Wiese is a scholar working on Oncology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Michael Wiese has authored 108 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Oncology, 57 papers in Molecular Biology and 43 papers in Infectious Diseases. Recurrent topics in Michael Wiese's work include Drug Transport and Resistance Mechanisms (78 papers), HIV/AIDS drug development and treatment (43 papers) and Cancer therapeutics and mechanisms (23 papers). Michael Wiese is often cited by papers focused on Drug Transport and Resistance Mechanisms (78 papers), HIV/AIDS drug development and treatment (43 papers) and Cancer therapeutics and mechanisms (23 papers). Michael Wiese collaborates with scholars based in Germany, Bulgaria and United Kingdom. Michael Wiese's co-authors include Ilza Pajeva, Kapil Juvale, Christoph Globisch, Sven Marcel Stefan, Jennifer Gallus, Henrik Müller, Katja Stefan, Veronika F.S. Pape, Vigneshwaran Namasivayam and Christa E. Müller and has published in prestigious journals such as Angewandte Chemie International Edition, SHILAP Revista de lepidopterología and Bioinformatics.

In The Last Decade

Michael Wiese

108 papers receiving 3.7k citations

Peers

Countries citing papers authored by Michael Wiese

Since Specialization

Citations

This map shows the geographic impact of Michael Wiese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Wiese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Wiese more than expected).

Fields of papers citing papers by Michael Wiese

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Wiese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Wiese. The network helps show where Michael Wiese may publish in the future.

Co-authorship network of co-authors of Michael Wiese

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Wiese. A scholar is included among the top collaborators of Michael Wiese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Wiese. Michael Wiese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Synthesis and biological assessment of new pyrimidopyrimidines as inhibitors of breast cancer resistance protein (ABCG2) 2021 ·Bioorganic Chemistry ·(unknown), (unknown), (unknown), Fakher Chabchoub, Michael Wiese, José Marco‐Contelles, Lhassane Ismaïli	17
2	Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach 2019 ·Journal of Medicinal Chemistry ·(unknown), Sven Marcel Stefan, (unknown), Vigneshwaran Namasivayam, Michael Wiese	26
3	Small‐molecule inhibitors of multidrug resistance‐associated protein 1 and related processes: A historic approach and recent advances 2018 ·Medicinal Research Reviews ·Sven Marcel Stefan, Michael Wiese	58
4	Synthesis and biological evaluation of quinazoline derivatives – A SAR study of novel inhibitors of ABCG2 2018 ·European Journal of Medicinal Chemistry ·(unknown), Jennifer Gallus, (unknown), Michael Wiese	35
5	Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1) 2016 ·Journal of Medicinal Chemistry ·(unknown), Sven Marcel Stefan, Michael Wiese	44
6	Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1) 2016 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·(unknown), Sven Marcel Stefan, Michael Wiese	22
7	Design, synthesis and biological evaluation of thiosemicarbazones, hydrazinobenzothiazoles and arylhydrazones as anticancer agents with a potential to overcome multidrug resistance 2016 ·European Journal of Medicinal Chemistry ·Veronika F.S. Pape, Szilárd Tóth, András Füredi, Kornélia Szebényi, Anna Lovrics, Pál Szabó, Michael Wiese, Gergely Szakács	97
8	HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2) 2015 ·Journal of Medicinal Chemistry ·(unknown), Michael Wiese	71
9	Interactions of the Multidrug Resistance Modulators Tariquidar and Elacridar and their Analogues with P‐glycoprotein 2013 ·ChemMedChem ·Ilza Pajeva, (unknown), (unknown), (unknown), (unknown), Michael Wiese	29
10	Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2) 2013 ·Bioorganic & Medicinal Chemistry ·Kapil Juvale, Jennifer Gallus, Michael Wiese	88
11	Are low molecular weight heparins able to sensitize chemoresistant tumor cells? 2013 ·International Journal of Clinical Pharmacology and Therapeutics ·(unknown), Ulrich Jaehde, Michael Wiese, Gerd Bendas	3
12	Recombinant Synthesis of Human ABCG2 Expressed in the Yeast Saccharomyces cerevisiae: an Experimental Methodological Study 2011 ·The Protein Journal ·(unknown), (unknown), (unknown), Christine A. Hrycyna, Michael Wiese	2
13	Targeted doxorubicin-liposomes as a tool to circumvent P-gp-mediated resistance in ovarian carcinoma cells 2010 ·International Journal of Clinical Pharmacology and Therapeutics ·(unknown), (unknown), Michael Wiese, Ulrich Jaehde, Gerd Bendas	5
14	Aromatic 2-(Thio)ureidocarboxylic Acids As a New Family of Modulators of Multidrug Resistance-Associated Protein 1: Synthesis, Biological Evaluation, and Structure−Activity Relationships 2009 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), Michael Gütschow, Michael Wiese	22
15	Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators 2009 ·Bioorganic & Medicinal Chemistry ·(unknown), Henrik Müller, Christoph Globisch, Ilza Pajeva, Michael Wiese	49
16	Structure–Activity Relationships of Tariquidar Analogs as Multidrug Resistance Modulators 2009 ·The AAPS Journal ·Ilza Pajeva, Michael Wiese	34
17	A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins 2008 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), (unknown), Michael Gütschow, Michael Wiese	19
18	In vitro and in vivo evaluation of WK‐X‐34, a novel inhibitor of P‐glycoprotein and BCRP, using radio imaging techniques 2006 ·International Journal of Cancer ·Veronika Jekerle, (unknown), Deborah A. Scollard, (unknown), Raymond M. Reilly, Micheline Piquette‐Miller, Michael Wiese	56
19	Inhibition of the Conjugation of PABA with Glycine in Vitro by Sulfamoyl Benzoic Acids, Sulfonamides, and Penicillins and Its Relation to Tubular Secretion 1998 ·Journal of Pharmaceutical Sciences ·(unknown), (unknown), (unknown), Michael Wiese, Joachim K. Seydel	5
20	A kinetic description of the fate of chemicals in biosystems 1991 ·The Science of The Total Environment ·Štefan Baláž, Michael Wiese, Joachim K. Seydel	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact